Cleaved-ITGA5 (E895) Antibody

What is Cleaved-ITGA5 (E895) Antibody and what does it specifically detect?

Cleaved-ITGA5 (E895) Antibody is a polyclonal antibody that specifically detects endogenous levels of the activated Integrin Alpha 5 Light Chain (ITGA5 LC) protein fragment resulting from proteolytic cleavage adjacent to glutamic acid at position 895 (E895) . This antibody recognizes the cleaved form rather than the intact protein, making it valuable for studying integrin activation and processing events. The specificity comes from the immunogen design, which utilizes a synthesized peptide derived from the C-terminal region of human ITGA5, typically within the amino acid range of 876-925 .

To validate specificity in your experiments, consider these methodological approaches:

• Run parallel Western blots comparing cleaved versus non-cleaved samples

• Include positive controls where ITGA5 cleavage is known to occur

• Implement peptide competition assays with the immunizing peptide to confirm binding specificity

How is the ITGA5 protein processed and what is the significance of E895 cleavage?

The ITGA5 gene encodes a preproprotein that undergoes post-translational cleavage in the extracellular domain to yield disulfide-linked light and heavy chains . The cleavage at E895 is particularly significant as it represents a key activation step. Proteolytic processing by PCSK5 (Proprotein Convertase Subtilisin/Kexin Type 5) mediates activation of the precursor . This processing enables the alpha 5 chain to associate with the beta 1 chain to form a functional fibronectin receptor (α5β1 integrin) .

The significance of this cleavage includes:

• Regulation of integrin activation state

• Modulation of binding affinity to extracellular matrix components

• Influence on downstream signaling cascades

• Potential role in cell migration, adhesion, and invasion

What are the recommended applications for Cleaved-ITGA5 (E895) Antibody?

Based on extensive validation data, Cleaved-ITGA5 (E895) Antibody is primarily recommended for Western Blot (WB) and ELISA applications . For optimal results in these applications, follow these methodological recommendations:

Western Blot Recommendations:

• Dilution range: 1:500-1:3000 (optimize for your specific sample type)

• Expected molecular weight: ~18kDa (observed in 293 cells), though the calculated molecular weight is approximately 115kDa for the full-length protein

• Include positive controls (e.g., cell lines known to express cleaved ITGA5)

• Consider gradient gels (10-20%) to effectively resolve the cleaved fragment

ELISA Recommendations:

• Recommended dilution: 1:20000

• Coating concentration: 1-10 μg/ml of capture antibody

• Blocking: 1-5% BSA in PBS is typically effective

• Detection system: HRP or AP-conjugated secondary antibodies work well

What are the proper storage and handling conditions for maintaining antibody activity?

To maintain optimal activity of Cleaved-ITGA5 (E895) Antibody, follow these evidence-based storage and handling recommendations:

• Store at -20°C for up to 1 year from receipt date

• Aliquot upon first thaw to avoid repeated freeze/thaw cycles that can degrade antibody activity

• The antibody is typically provided in liquid form in PBS containing 50% glycerol, 0.5% BSA (or 0.5% protective protein), and 0.02% sodium azide, pH 7.4

• For short-term storage (less than 1 month), 4°C is acceptable

• Centrifuge the vial before opening to ensure recovery of all contents

• Avoid contamination by using sterile technique when handling

How should I design positive and negative controls for experiments using Cleaved-ITGA5 (E895) Antibody?

Proper control design is essential for interpreting results with Cleaved-ITGA5 (E895) Antibody. Consider implementing these methodological approaches:

Positive Controls:

• 293 cells, which have been validated to express the cleaved form (~18kDa band)

• Cells treated with agents known to induce ITGA5 cleavage (e.g., certain proteases or activators)

• Recombinant cleaved ITGA5 protein fragments (if available)

Negative Controls:

• Cells with ITGA5 knockdown (siRNA or CRISPR)

• Pre-immune serum at equivalent concentration to primary antibody

• Primary antibody pre-absorbed with immunizing peptide

• Secondary antibody only (to detect non-specific binding)

Validation Approach:

• Run parallel samples with cleaved and non-cleaved conditions

• Confirm specificity using peptide competition assays

• Validate using multiple detection methods (e.g., WB and ELISA)

What sample preparation techniques maximize detection of cleaved ITGA5?

Sample preparation significantly impacts the detection of cleaved ITGA5. For optimal results:

Protein Extraction:

• Use RIPA buffer supplemented with protease inhibitors to prevent artificial cleavage during extraction

• Include phosphatase inhibitors if studying phospho-dependent events

• Maintain cold temperatures throughout extraction to minimize protein degradation

• Consider including specific inhibitors of PCSK5 if studying natural cleavage levels

Sample Processing:

• Do not boil samples before loading if detecting membrane proteins (heat at 70°C for 10 minutes instead)

• Use fresh samples when possible; if freezing is necessary, snap-freeze in liquid nitrogen

• For cell fractionation, separate membrane fractions where integrins naturally localize

• Calculate protein concentration and load equal amounts (typically 20-50μg total protein per lane)

Western Blot Optimization:

• Consider using gradient gels (4-20%) for better resolution of cleaved fragments

• Transfer proteins to PVDF membranes (preferred over nitrocellulose for some integrin antibodies)

• Block with 5% BSA rather than milk to reduce background

What dilution optimization strategies are recommended for different experimental systems?

Optimization of antibody dilution is crucial for obtaining specific signals while minimizing background. Based on the product specifications, implement this systematic approach:

Western Blot Dilution Optimization:

• Start with the mid-range recommended dilution (1:1000)

• Perform a dilution series (e.g., 1:500, 1:1000, 1:2000, 1:3000)

• Include positive and negative controls for each dilution

• Select the dilution that provides the best signal-to-noise ratio

ELISA Dilution Optimization Table:

Factors Affecting Optimal Dilution:

• Sample type (cell lysate, tissue extract, purified protein)

• Expression level of target protein

• Detection method (chemiluminescence, fluorescence, colorimetric)

• Incubation conditions (time, temperature)

How can Cleaved-ITGA5 (E895) Antibody be used to investigate integrin-mediated signaling pathways?

Leveraging Cleaved-ITGA5 (E895) Antibody for signaling research requires sophisticated experimental approaches:

Co-immunoprecipitation Studies:

• Use Cleaved-ITGA5 (E895) Antibody to pull down associated signaling complexes

• Detect interaction partners by mass spectrometry or Western blot

• Compare signaling complex formation between cleaved and uncleaved states

Phosphorylation Analysis:

• Examine how ITGA5 cleavage affects downstream phosphorylation events

• Focus on FAK, Src, and paxillin phosphorylation states as these are key integrin signaling mediators

• Implement phospho-specific antibodies in parallel with Cleaved-ITGA5 (E895) Antibody

Functional Correlation Studies:

• Correlate cleavage status with cell adhesion, migration, or invasion phenotypes

• Examine fibronectin-binding capacity in relation to cleavage status

• Investigate RGD-dependent signaling pathways, as α5β1 integrin recognizes the RGD sequence in its ligands

Can this antibody be used in conjunction with therapeutic ITGA5-targeting strategies?

Integrin α5β1 has emerged as a therapeutic target, particularly in cancer research. Cleaved-ITGA5 (E895) Antibody can complement therapeutic research in several ways:

Therapeutic Antibody Evaluation:

• Use Cleaved-ITGA5 (E895) Antibody to monitor cleavage status during treatment with anti-α5β1 therapeutic antibodies

• Compare with research findings on PF-04605412, a fully human, Fc-engineered anti-α5β1 IgG1 mAb with anti-angiogenic properties

• Assess whether therapeutic antibodies affect the cleavage rate or pattern of ITGA5

Biomarker Development:

• Evaluate cleaved ITGA5 as a potential biomarker for response to integrin-targeting therapies

• Correlate cleavage patterns with therapeutic outcomes in preclinical models

• Design sandwich ELISA approaches using Cleaved-ITGA5 (E895) Antibody for monitoring treatment effects

Combinatorial Therapeutic Approaches:

• Investigate how ITGA5 cleavage status affects response to other therapies (e.g., chemotherapy, targeted therapy)

• Examine potential synergistic effects between ITGA5-targeting and other therapeutic modalities

What methodologies can be used to study ITGA5 cleavage dynamics in live cells?

While Cleaved-ITGA5 (E895) Antibody is primarily validated for WB and ELISA , researchers interested in live cell dynamics can implement complementary approaches:

Fluorescence-Based Approaches:

• Generate fluorescently-tagged ITGA5 constructs with internal sensors that report on cleavage events

• Design FRET-based reporters where fluorophores are positioned to detect conformational changes upon cleavage

• Use fluorescence recovery after photobleaching (FRAP) to monitor mobility changes associated with cleavage

Live Cell Protease Activity Monitoring:

• Implement substrate-based reporters specific for PCSK5 (the protease that mediates ITGA5 activation)

• Design cell-based assays that couple cleavage events to easily detectable signals (e.g., luciferase activity)

• Use proximity-based assays (BioID, APEX) to identify transient interactions during cleavage

Validation Strategy:

• Confirm findings from live cell assays using fixed cell approaches with Cleaved-ITGA5 (E895) Antibody

• Correlate real-time observations with endpoint measurements of cleavage products

• Implement genetic approaches (CRISPR-based mutation of E895) to validate specificity

How can I resolve discrepancies between observed and expected molecular weights?

A notable discrepancy exists between the observed molecular weight of cleaved ITGA5 (~18kDa in Western blots) and the calculated full-length molecular weight (~115kDa) . This is a common source of confusion that can be addressed methodologically:

Understanding the Discrepancy:

• The 115kDa represents the full-length protein, while 18kDa represents the cleaved light chain fragment

• Post-translational modifications (glycosylation, phosphorylation) can alter apparent molecular weight

• The cleavage at E895 generates specific fragments with distinct molecular weights

Verification Approaches:

• Run molecular weight ladders flanking your samples

• Include positive control samples with known molecular weights

• Consider using gradient gels for better resolution

• Perform peptide competition assays to confirm specificity of bands

Analytical Methods for Verification:

• Mass spectrometry analysis of the detected band

• 2D gel electrophoresis to separate based on both isoelectric point and molecular weight

• Sequential probing with antibodies targeting different domains of ITGA5

What are common sources of false positive and false negative results?

Understanding potential artifacts is critical for accurate interpretation of experiments using Cleaved-ITGA5 (E895) Antibody:

Potential False Positives:

• Non-specific binding to other cleaved proteins with similar motifs

• Artificially induced cleavage during sample preparation (use fresh protease inhibitors)

• Cross-reactivity with related integrin family members

• Secondary antibody binding to endogenous immunoglobulins in certain sample types

Potential False Negatives:

• Epitope masking due to protein-protein interactions

• Sample degradation leading to loss of epitope recognition

• Insufficient antigen retrieval in fixed samples

• Suboptimal concentration of primary or secondary antibody

Validation Strategies to Minimize Errors:

• Multiple detection methods (WB, ELISA) to confirm results

• Genetic manipulation (overexpression, knockdown) to validate specificity

• Peptide competition assays to confirm antibody specificity

• Use of multiple antibodies targeting different epitopes of the same protein

How should results be interpreted in the context of integrin activation states?

Interpreting results from Cleaved-ITGA5 (E895) Antibody requires understanding the relationship between cleavage and activation:

Correlation with Activation:

Integrated Analysis Approach:

• Detect cleavage status using Cleaved-ITGA5 (E895) Antibody

• Assess functional activation through adhesion assays or ligand binding studies

• Examine downstream signaling events (FAK phosphorylation, etc.)

• Correlate with biological outcomes (migration, proliferation, etc.)

Interpreting Heterogeneity:

• Cell populations may show heterogeneous cleavage patterns

• Consider single-cell approaches to resolve population heterogeneity

• Analyze spatiotemporal dynamics to understand activation patterns

How can Cleaved-ITGA5 (E895) Antibody be used to study integrin's role in cancer and therapeutic resistance?

Integrins play critical roles in cancer progression, and cleaved ITGA5 may serve as an important biomarker or therapeutic target:

Cancer Research Applications:

• Compare cleaved ITGA5 levels between normal and malignant tissues

• Correlate cleavage status with invasion, metastasis, and therapy resistance

• Examine how ITGA5 cleavage contributes to tumor microenvironment interactions

Therapeutic Resistance Studies:

• Investigate whether altered ITGA5 cleavage contributes to resistance mechanisms

• Examine cell adhesion-mediated drug resistance in relation to ITGA5 cleavage status

• Develop combination approaches targeting both ITGA5 and resistance pathways

Methodological Approach:

• Use cleaved-ITGA5 antibody to screen patient-derived xenografts or clinical samples

• Correlate expression with treatment response and clinical outcomes

• Implement genetic approaches to modulate cleavage and assess impact on drug sensitivity

What are the recommended approaches for analyzing ITGA5 cleavage in relation to other integrin family members?

Integrins function as part of a complex network, and analyzing ITGA5 in isolation may provide incomplete information:

Comparative Analysis Framework:

• Use panel approaches to simultaneously analyze multiple integrin family members

• Compare ITGA5 cleavage with processing of other alpha subunits (e.g., αV)

• Examine beta-partner associations and how they're affected by alpha-chain cleavage

Multi-Integrin Analysis Table:

Analytical Considerations:

• Consider compensation controls when performing multiplexed analyses

• Account for potential overlapping epitopes when using multiple antibodies

• Implement sequential immunoprecipitation to resolve integrin heterodimer compositions

How can researchers integrate Cleaved-ITGA5 (E895) data with modern omics approaches?

Modern research increasingly integrates antibody-based detection with broader systems biology approaches:

Integration with Genomics:

• Correlate ITGA5 cleavage patterns with gene expression profiles

• Examine how genetic variations in ITGA5 or PCSK5 (the processing enzyme) affect cleavage patterns

• Implement CRISPR screens to identify genes modulating ITGA5 cleavage

Proteomics Integration:

• Use Cleaved-ITGA5 (E895) Antibody for immunoprecipitation followed by mass spectrometry

• Identify interaction partners specific to cleaved versus uncleaved forms

• Implement thermal proteome profiling to examine stability changes upon cleavage

Multi-Omics Framework:

• Layer cleaved ITGA5 data with transcriptomics, proteomics, and phospho-proteomics

• Develop computational models predicting cleavage based on cellular context

• Implement machine learning approaches to identify patterns associated with specific biological outcomes